The conference will cover themes such as:

• The role of p53 in upcoming cancer therapeutics

• Models for identifi cation of drug targets
applicable to p53

• Influencing the p53 activation cascade

• How to introduce p53 therapeutics into large
scale patient care

Who will be there?

VPs Directors, Heads, and Managers in:

• Cancer research
• Pharmaceutical Research and Development
• Oncology
• Drug Discovery
• Medicinal Chemistry
• Production Planning
• Immunology
• Regulatory Affairs
• Pricing and marketing
• Early development
• Clinical Science

Day 1 of Conference, Thursday 20th November 2008

09:30 Registration and refreshments

10:00 Opening address from the chair

Jola Gore-Booth
Chief Executive
Europacolon

10:10 Where are we and where do we go from here?

• P53 research in a therapeutic perspective

• The direction of the p53 research and how to
improve the therapeutic
value of the research

• The future: what is the goal?

Wolfgang Deppert
Professor
Heinrich-Pette Institute

10:50 The key to success in cancer therapy

• Discussing the different approaches to improve
therapeutic value of research

• Examine how to chose and be chosen

• The role of p53 in upcoming cancer therapeutics

Brian Lovatt
Managing Director
Cancer Deals

11:30 Morning refreshments

11:50 Drug discovery in the p53 pathway using
phenotypic screens

• Phenotypic screens offers the unique possibility
to analyse entire genomes

• The screening can be successfully applied to the
identification of drug targets

• A valuable tool for future target discovery
efforts

David Lane
Director of the Cancer Research UK Transformation Research Group
University of Dundee

12:30 Targeted rescue of oncogenic mutants of p53

• Mutation Y220C causes temperature-sensitive
global unfolding

• In-Silico design gives leads to fill the induced
cavity
• Suitable leads re-stabilise Y220C for crystal
structures give improved design and fine
biological testing

Allan Fersht
Director
MRC Centre for Protein Engineering

13:10 Networking lunch

14:30 Selective Chk1 inhibitors differentially sensitize p53-
deficient cancer cells to cancer therapeutics

• Chk1 is the key mediator for DNA damage
checkpoint in p53 deficient cells

• Chk1-mediated cell cycle arrest provides an
escape mechanism to conventional cancer
therapeutics

• Inhibition of Chk1 abrogates DNA damage
checkpoints in p53 deficient
cancer cells but not p53 proficient cells

• Chk1 inhibitor selectively enhances drug-induced
apoptosis in p53 deficient cancer cells

Zehan Chen
Research Investigator, Cancer Research
Abbott Laboratories

15:10 Small molecules as MDM2 inhibitors

• Finding small molecules to target MDM2

• Using antagonists of the MDM2-p53 protein-
protein interaction

• Discuss the implications of the inhibition

Maxwell Cummings
Senior Scientist in Molecular Design and Informatics
Johnson & Johnson

15:50 Afternoon refreshments

16:10 The future role of small molecules in cancer therapy

• The major classes of small molecules possible
for p53 therapy

• Discussing the diversity of chemo types reported
to disrupt the interaction

• Examination of the screening approaches and
technologies for identification

Hilary Calvert
Professor of Medical Oncology
University of Newcastle

16:50 Panel Discussion: The role of the MDM2 pathway in cancer therapy

• Is the MDM2 pathway a potential target for
cancer therapy

• How should the MDM2 pathway be used for maximum
impact

• Is large scale treatment a possibility?

17:30 Closing remarks from the chair

17:35 Networking Drinks Reception

Take your discussions further and build new relationships in
a relaxed and informal setting.

Day 2, Friday 21st November 2008

09:30 Registration and refreshments

10:00 Opening address from the chair

Jola Gore-Booth
Chief Executive
Europacolon

10:10 Potent inhibition of carcinogen-bioactivating
cytochrome P450 1B1 by the p53 inhibitor
pifithrin alpha

• The chemical compound pifithrin alpha (PFT-) has
been isolated for its ability to suppress p53-
mediated transcriptional activation and has been
presented as a specific inhibitor of p53
signalling

• Examining the effects of PFT- on toxic effects
of chemical carcinogens
requiring cytochrome P450 related bioactivation, such as DNA adducts
formation and apoptosis in human cultured cells

• Discussing an unexpected andp53-indipendent
action of PFT-: inhibition
of cytochrome P450 enzyme activities,indicating that caution may be
required when using this chemical compound as a specific p53 inhibitor

Lydie Sparfel
UMR-INSERM U620
University of Rennes

10:50 In vivo and in vitro models for analyzing mutant p53 gain of function

• A mouse model for oncogene-induced mammary carcinogenesis
demonstrates mutant p53 gain of function in vivo

• Development and properties of a mouse mammary carcinoma stem cell
line that forms mammary carcinomas in immunocompetent syngeneic
,mice and is a suitable tool for analyzing potential drug targets

• Elimination of mutant p53 expression in a glioblastoma cell line
eliminates its oncogenic properties in vitro and in vivo

• Possible mechanisms of mutant p53 gain of function

Gernot Wolkersdorfer
Department of Internal Medicine
University of Technology Dresden

11:30 Morning refreshments

11:50 Regulating p53 through MDM2

• Exploring the current knowledge of the role of post translational
modifications of MDM2 and their functional relevance

• Discussing the importance of MDM2 as a target for new cancer therapeutics

Stefano Marullo
Director of Research, Department of Cellular Biology
Institut Cochin

12:30 Reactivation of mutant p53: molecular mechanisms and therapeutic potential

• Mutant p53 reactivation will restore p53-dependent apoptosis, resulting
in efficient removal of tumor cells

• Peptides and small molecules restores the active conformation and DNA binding to mutant p53

• The restoration of p53 induce p53-dependent suppression of tumor cell
growth in vivo and in vitro

Klas Wiman
Professor
Karolinska Institutet

13:10 Networking lunch

14:30 From science to product – A regulatory perspective

• Discussing the regulatory process for approving targeted oncology treatments

• Points to consider for gaining regulatory approval

• Compiling the dossier

Colleen Mockbee
Associate Director, Regulatory Affairs Oncology
Eli Lilly*

15:10 Presentation to be confirmed

15:50 Afternoon refreshments

16:10 Can p53 cancer therapy be more than a small niche?

• Examining the future of p53 drugs for the European market

• Is p53 therapy to specified?

• Discussing how to us p53 therapy as a complement to traditional cancer therapy

Chris Teale
Director, Global Pricing and Market Access Strategy
AstraZeneca*

16:50 Panel Discussion: How should p53 therapies be
used to have the greatest effect?

• Examining the therapeutic prospects

• Discussing the regulatory and marketing aspects

• Consider the implications of large scale
treatment with p53 products

17:30 Chair’s closing remarks and end of conference